Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801
Por:
Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM and Márquez-Rodas, I
Publicada:
1 jun 2026
Ahead of Print:
1 dic 2025
Resumen:
BackgroundThe clinical presentation of melanoma of unknown primary (MUP) and its treatment patterns remain incompletely characterized.MethodsGEM1801 is a prospective, observational study in Spain enrolling patients with advanced melanoma. This analysis describes the clinical features and outcomes of patients with MUP.ResultsFrom August 2018 to December 2022, 893 evaluable patients were enrolled, of whom 133 (14.9%) had MUP. Median age was 63 years (range 24-93); 81 (60.9%) were men; 117 (88.0%) had distant metastases; lactate dehydrogenase (LDH) was elevated in 50 (37.6%); and 79 (54.9%) had BRAF-mutated tumors. Compared with patients with a known primary, immunotherapy was prescribed less frequently (adjuvant: 15.5% vs 27.2%, p = 0.007; first-line metastatic: 53.6% vs 64.0%, p = 0.039). Median progression-free survival (PFS) was 18.9 months (95% CI: 4.4-NR), 13.3 months (95% CI: 7.1-27.5), and 6.7 months (95% CI: 3.5-NR), and median overall survival (OS) was 24.9 months (95% CI: 24.1-NR), 13.9 months (95% CI: 8.3-NR), and 17.9 months (95% CI: 9.6-NR) in patients with BRAF-mutated tumors treated with immunotherapy, BRAF-mutated tumors treated with targeted therapy, and BRAF-wild-type tumors treated with immunotherapy, respectively.ConclusionsIn Spain, MUP is characterized by multi-organ involvement and frequent brain metastases and was associated with worse outcomes than the overall melanoma cohort. A diagnosis of MUP appears to influence treatment allocation, particularly regarding immunotherapy. When stratified by BRAF status and treatment type, no survival differences were observed between MUP and melanoma of known primary, except for OS among patients with MUP and BRAF-mutated tumors treated with immunotherapy.Clinical trial identificationclinicaltrials.gov: NCT03605771.
Filiaciones:
Cerezuela-Fuentes, P:
Hosp Clin Univ Virgen de La Arrixaca, Med Oncol Dept, Inst Murciano Invest Sanitaria IMIB, Ciudad De Murcia, Spain
Piñero-Madrona, A:
Univ Virgen de La Arrixaca, Hosp Clin, Dept Surg, IMIB Arrixaca, Ciudad De Murcia, Spain
Muñoz-Couselo, E:
Hosp Univ Vall dHebron, Med Oncol Dept, Barcelona, Spain
Vall dHebron Inst Oncol VHIO, Barcelona, Spain
:
Hosp Germans Trias I Pujol, Inst Catalan Oncol, Med Oncol Dept, ICO Badalona, Badalona, Spain
Berciano-Guerrero, MA:
Hosp Univ Reg & Virgen de La Victoria HURyVV, Unidad Interctr Oncol, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
Majem, M:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
Espinosa, E:
La Paz Univ Hosp, Med Oncol Dept, CIBERONC, Madrid, Spain
Soria, A:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
Castaño, AG:
Hosp Univ Marques de Valdecilla, Med Oncol Dept, Santander, Spain
Crespo, G:
Hosp Univ Burgos, Med Oncol Dept, Burgos, Spain
Sanz, LG:
Hosp Univ Puerta de Hierro, Med Oncol Dept, Madrid, Spain
de la Rosa, CA:
Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain
Fernández-Morales, LA:
Hosp Univ Parc Tauli, Med Oncol Dept, Sabadell, Spain
Puértolas, T:
Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain
Rodríguez, JF:
Hosp Univ Rio Hortega, Med Oncol Dept, Valladolid, Spain
de la Borbolla, MR:
Univ Hosp Valme, Med Oncol Dept, Seville, Spain
Bellido, L:
Complejo Asistencial Univ Salamanca, Med Oncol Dept, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
Castro, RL:
Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain
Pérez, VN:
Hosp Costa del Sol, Med Oncol Dept, Marbella, Spain
Arroyo, FRG:
Complejo Hosp Univ Pontevedra, Med Oncol Dept, Pontevedra, Spain
Guzmán, JCV:
Hosp Gen Ciudad Real, Med Oncol Dept, Ciudad Real, Spain
Balea, BC:
Hosp Univ Lucus Augusti, Serv Med Intens, Lugo, Spain
Hernández, B:
Hosp Univ La Princesa, Med Oncol Dept, Madrid, Spain
Algarra, SM:
Clin Univ Navarra, Med Oncol Dept, Pamplona, Spain
Márquez-Rodas, I:
Univ Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain
Hosp Univ San Pedro de Alcantara, Med Oncol Dept, Caceres, Spain
|